Working Together Developing Biomedical Product(s) to Combat COVID 19.
Ruhvenile Biomedical, India, and RNA SMART HEALTH, Paris, France, have been collaborating to develop RNA-based therapeutics to combat COVID-19 and future infectious pandemic. This collaboration aims to provide engineered antibodies targeting neurodegenerative diseases based on genetic editing techniques. The ultimate scope is to translate these novel engineered antibodies into readily-available diagnostic kits, research resources, and clinical therapeutics.
Will also check:
- Comprehensive short- and long-term follow-up of COVID-19-associated neurological symptoms in patients with COVID-19 infection.
- Next-Generation, Multi-function antibodies to target enveloped-viruses.
- The company benefits from 10-years’ experience with cutting-edge technologies and know-how in Genetic Code Expansion and gene editing (CRISPR-Cas9).